Live Breaking News & Updates on Karyopharm Therapeutics Company Profile

Stay updated with breaking news from Karyopharm therapeutics company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Target Price at $8.00

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target […] ....

Reshma Rangwala , Robertw Baird , Nisa Investment Advisors , Advisor Group Holdings Inc , Karyopharm Therapeutics Company Profile , Karyopharm Therapeutics Inc , Life Insurance Co , Janney Montgomery Scott , Its Selective Inhibitor Of Nuclear Export , Securities Exchange Commission , Victory Capital Management Inc , Karyopharm Therapeutics , Get Rating , Exchange Commission , Investment Advisors , Group Holdings , Montgomery Scott , Victory Capital Management , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti ,

HC Wainwright Trims Karyopharm Therapeutics (NASDAQ:KPTI) Target Price to $10.00

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its price target lowered by HC Wainwright from $16.00 to $10.00 in a research note released on Friday, The Fly reports. A number of other analysts have also recently issued reports on the company. Morgan Stanley dropped their price objective on Karyopharm Therapeutics from $7.00 to $5.00 and […] ....

Piper Sandler , Reshma Rangwala , Richarda Paulson , Karyopharm Therapeutics Inc , Karyopharm Therapeutics Company Profile , Morgan Stanley , Vanguard Group Inc , Securities Exchange Commission , Metlife Investment Management , Swiss National Bank , Its Selective Inhibitor Of Nuclear Export , Charles Schwab Investment Management Inc , Karyopharm Therapeutics , Get Rating , Moderate Buy , Exchange Commission , National Bank , Life Investment Management , Charles Schwab Investment Management , Schwab Investment Management , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti , Lower Price Target , Hc Wainwright ,

Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Declines By 7.0%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 17,760,000 shares, a decline of 7.0% from the March 31st total of 19,090,000 shares. Based on an average trading volume of 2,350,000 shares, the […] ....

Sohanya Roshan Cheng , Reshma Rangwala , Piper Sandler , Karyopharm Therapeutics Company Profile , Morgan Stanley , Karyopharm Therapeutics Inc , Armistice Capital , Vanguard Group Inc , Its Selective Inhibitor Of Nuclear Export , Marshall Wace , Karyopharm Therapeutics , Get Rating , Roshan Cheng , Street Corp , Partners Management , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti ,

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) EVP Sells $27,418.50 in Stock

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) EVP Reshma Rangwala sold 6,770 shares of the business’s stock in a transaction on Thursday, April 20th. The shares were sold at an average price of $4.05, for a total transaction of $27,418.50. Following the transaction, the executive vice president now directly owns 158,230 shares of the company’s […] ....

Piper Sandler , Reshma Rangwala , Swiss National Bank , Metlife Investment Management , Morgan Stanley , Vanguard Group Inc , Securities Exchange Commission , Its Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Company Profile , Charles Schwab Investment Management Inc , Karyopharm Therapeutics Inc , Karyopharm Therapeutics , Get Rating , Exchange Commission , National Bank , Life Investment Management , Charles Schwab Investment Management , Schwab Investment Management , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti , Insider Trading , Nsider Trades ,

Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Rises By 14.1%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 19,090,000 shares, a growth of 14.1% from the March 15th total of 16,730,000 shares. Based on an average daily trading volume, of 2,600,000 shares, the days-to-cover ratio […] ....

Michael Mason , Richarda Paulson , Piper Sandler , Karyopharm Therapeutics Inc , Morgan Stanley , Nisa Investment Advisors , Mackenzie Financial Corp , Karyopharm Therapeutics Company Profile , Its Selective Inhibitor Of Nuclear Export , Securities Exchange Commission , Advisor Group Holdings Inc , Northern Trust Corp , Life Insurance Co , Karyopharm Therapeutics , Get Rating , Exchange Commission , Financial Corp , Trust Corp , Investment Advisors , Advisor Group Holdings , Group Holdings , Therapeutics Trading Down , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti ,